Press Release

Press Release

Return to Press Releases


CAMBRIDGE, MASS. and CAMBRIDGE, U.K. – October 11, 2016 – Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) product platform, announced today the appointment of Peter U. Park, Ph.D., as Vice President of Oncology Research in its Cambridge, MA office.

“We are pleased to welcome Peter to Bicycle and believe he will play an integral role as we advance our first Bicycle Drug Conjugate® program for oncology into the clinic and explore other applications of the platform,” stated Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.

Dr. Park was previously Vice President of Biology at Mersana Therapeutics, Inc., where he established a portfolio of novel antibody drug conjugate (ADC) products and managed the internal and collaboration pipeline. Prior to that, he served at ImmunoGen, Inc., for 10 years, most recently as Senior Director of Discovery Research where he oversaw the discovery research portfolio for the development of antibody and ADC therapies for oncology. In previous roles, he co-invented and advanced three compounds into clinical development and oversaw many other discovery projects into late discovery and pre-clinical development. Dr. Park received his B.S. and Ph.D. in Biology from the Massachusetts Institute of Technology.

“Bicycle Therapeutics has built an unrivalled drug discovery technology capable of identifying proprietary bicyclic-peptides with high affinity and selectivity for the therapeutic target. Furthermore, the ability to modify the pharmacokinetic profile of

these emerging drugs offers a range of options with significant promise in many diseases, including oncology,” said Dr. Park.

This appointment aligns with the broader Bicycle strategy of establishing a U.S. operating base led by Ros Deegan, President of Bicycle, who commented, “We are delighted to have Peter join us to establish our U.S. oncology group. His extensive experience and proven track record in antibody and antibody drug conjugate therapeutics make him the ideal executive for this role.”

About Bicycle Therapeutics

Bicycle Therapeutics is developing a new class of medicines to treat oncology and other diseases based on its proprietary bicyclic peptide (Bicycle®) product platform. Bicycles exhibit the affinity and exquisite target specificity usually associated with antibodies. Their small size enables rapid and deep tissue penetration, allowing tissues and tumours to be targeted from within. Their peptidic nature provides a tunable pharmacokinetic half-life and a renal route of clearance, thus avoiding the liver and gastrointestinal tract toxicity often seen with other drug modalities. Bicycle Therapeutics is rapidly advancing towards the clinic with its lead programs using Bicycle Drug Conjugates® to selectively deliver toxins to tumours. Bicycle Therapeutics is collaborating in oncology and other areas to realize the full potential of the technology. Bicycle Therapeutics’ unique intellectual property is based on the work initiated at the MRC Laboratory of Molecular Biology in Cambridge, U.K., by the scientific founders of the company, Sir Gregory Winter and Professor Christian Heinis. Bicycle Therapeutics is headquartered in Cambridge, U.K., with a U.S. operations subsidiary in Cambridge, Massachusetts. For more information, visit

For further information, please contact:

Ten Bridge Communications (U.S.)
Cara Mayfield

Consilium Strategic Communications (EU)
Mary-Jane Elliott / Chris Gardner / Ivar Milligan
+44 20 3709 5700